IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)

P1, N=94, Recruiting, Mayo Clinic | Trial completion date: Feb 2029 --> May 2029 | Trial primary completion date: Feb 2028 --> May 2028

We validated these clinical and molecular findings in an independent validation cohort of 302 NPM1 mut patients enrolled in the acute myeloid leukemia study group (AMLSG) 09-09 clinical trial, which included the administration of all-trans retinoic acid (ATRA) to all patients and a randomization for gemtuzumab ozogamicin. In this cohort, the APL-like immunophenotype was associated with events occurring within the first 15 days but did not influence mortality, likely due to protocol-driven patient selection. Our findings have important clinical implications that warrant the development of studies exploring disease-tailored clinical measures to mitigate the risk of early vascular events, as in current APL management.

Multivariable and LASSO analyses identified independent risk factors: male gender (OR=3.28, p = 0.025), higher blast percentage (OR=1.03, p = 0.006), elevated baseline uric acid (OR=1.01, p = 0.011), IDH1/2 mutation (OR=4.86, p = 0.005), and a trend with venetoclax-based therapy (OR=7.52, p = 0.072)...Adequate urine output reduced TLS risk, while excessive positive fluid balance correlated with severe TLS (p = 0.046). Individualized fluid management and 72-hour intensive monitoring are critical for high-risk groups.

The striking reductions in tumor 2HG and tCho levels early following initiation of targeted therapy using an IDH inhibitor suggest that MRS may provide an important tool for monitoring treatment response of lower-grade gliomas.

Key advancements include the integration of FLT3 inhibitors into intensive chemotherapy and the emergence of venetoclax...Innovations such as the liposomal formulation CPX-351 and oral formulations of CC-486 and oral decitabine/cedazuridine have further optimized treatment delivery and improved patient quality of life...Current research is actively exploring next-generation inhibitors, antibody-drug conjugates, and cellular immunotherapies such as BiTEs and CAR-T cells. This review summarizes the recent pharmacological evolution in AML and discusses how these emerging therapies bring us closer to the ultimate goal of achieving a definitive cure.

Notably, the oncogenic idh1*R132H variant also rescued the pronephric defects induced by idh1 knockdown, indicating that its neomorphic activity is absent under embryonic metabolic conditions. These findings identify Idh1 and Idh2 as key regulators of pronephric morphogenesis and reveal a developmental function of Idh1 that is distinct from its canonical catalytic role.

KRAS G12C-mutated NSCLC is clinically aggressive and frequently shows solid growth with rhabdoid, plasmacytoid, or SCC-like morphology, which may lead to misclassification and missed genetic testing. Immunohistochemistry and molecular profiling are essential for accurate classification and enabling targeted therapy.

Additionally, base-level confirmation for KRAS1 (exon 2) and IDH2 (exon 4) through Sanger sequencing, which verified the range of PCR-RFLP-detected mutations. Our findings in the genetic landscape highlight the complexity of hepatocarcinogenesis but also point to potential therapeutic exploitation.

Disease-modifying activity with decreases in mutated clones is rare. Although the exact mechanism behind our findings remains undetermined, they are in line with the proposed effects of HMA on epigenetics in leukemia cells.

Finally, we outline emerging directions beyond canonical nodes, including modulation of the p53-MDM2/MDM4 axis, ferroptosis control through AIFM2/FSP1, and innate immune pathways such as CD47-SIRPa and the stimulator of interferon genes (STING). Overall, the field is shifting from single-target inhibition toward integrated strategies that combine precise molecular targeting with an understanding of signaling network dynamics, resistance evolution, and therapeutic vulnerabilities.

Results from molecular docking simulations demonstrated a remarkable binding specificity effect between TPHP and target proteins. This effect is highly likely to be the crucial factor contributing to the development of glioma.

In conclusion, MDS patients with MF had specific genetic lesions. The integration of mutational profiling, including the potentially favorable impact of MPL mutations, with conventional scoring systems enables refined prognostic assessment and warrants further validation to guide risk-adapted therapeutic strategies.